Allen Michael H, Hirschfeld Robert M, Wozniak Patricia J, Baker Jeffrey D, Bowden Charles L
University of Colorado School of Medicine, 4200 East 9th Ave., Box A011-95, Denver, CO 80220, USA.
Am J Psychiatry. 2006 Feb;163(2):272-5. doi: 10.1176/appi.ajp.163.2.272.
Several studies have shown that achieving adequate serum valproate levels is critical to rapid stabilization of acute mania, but estimates of the target therapeutic level have been imprecise. A post hoc analysis of pooled intent-to-treat data from three randomized, placebo-controlled studies of divalproex treatment for acute mania was performed to test a hypothesized linear relationship between serum concentration and response and to determine optimal blood levels for treatment of acute mania.
Subjects (N=374) were stratified into seven groups (six valproate serum level ranges and placebo), and effect size was determined for each. Linearity of dose response was tested with both parametric and nonparametric techniques. ANOVA was used to compare the response at each serum level range with that of placebo as well as the lowest valproate level (< =55.0 microg/ml). The mean serum valproate level was then determined for all subjects with an effect size greater than or equal to the maximal effect derived from linear modeling.
The fit of blood level and response to a linear model was good. Efficacy was significantly greater than placebo beginning at the 71.4-85.0 microg/ml range and for all higher valproate levels; the 94.1-107.0 and >107.0 microg/ml groups were superior to the lowest valproate serum level group. The effect size associated with highest serum levels (>94 microg/ml) was 1.06 (0.59 after placebo correction). Subjects obtaining this effect or greater (N=84) had a mean serum level of 87.5 microg/ml. Blood levels in the lowest effective range were 60% more effective than placebo and in the higher ranges were 120% more effective. Tolerability appeared similar for all groups.
The results of this study suggest that there is a linear relationship between valproate serum concentration and response and that the target blood level of valproate for best response in acute mania is above 94 microg/ml.
多项研究表明,使血清丙戊酸盐水平达到适当程度对于急性躁狂症的快速稳定至关重要,但目标治疗水平的估计并不精确。对三项丙戊酸二丙酯治疗急性躁狂症的随机、安慰剂对照研究的汇总意向性治疗数据进行事后分析,以检验血清浓度与反应之间的假设线性关系,并确定治疗急性躁狂症的最佳血药水平。
将受试者(N = 374)分为七组(六个丙戊酸盐血清水平范围和安慰剂组),并确定每组的效应大小。使用参数和非参数技术测试剂量反应的线性。方差分析用于比较每个血清水平范围与安慰剂以及最低丙戊酸盐水平(<=55.0微克/毫升)的反应。然后确定所有效应大小大于或等于线性模型得出的最大效应的受试者的平均血清丙戊酸盐水平。
血药水平与反应对线性模型的拟合良好。从71.4 - 85.0微克/毫升范围开始以及所有更高的丙戊酸盐水平,疗效均显著高于安慰剂;94.1 - 107.0微克/毫升组和>107.0微克/毫升组优于最低丙戊酸盐血清水平组。与最高血清水平(>94微克/毫升)相关的效应大小为1.06(安慰剂校正后为0.59)。获得此效应或更大效应的受试者(N = 84)的平均血清水平为87.5微克/毫升。最低有效范围内的血药水平比安慰剂有效60%,在较高范围内则有效120%。所有组的耐受性似乎相似。
本研究结果表明,丙戊酸盐血清浓度与反应之间存在线性关系,急性躁狂症最佳反应的丙戊酸盐目标血药水平高于94微克/毫升。